The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Publication|Articles|January 2, 2024
- Pharmaceutical Technology, January 2024
- Volume 48
- Issue 1
- Pages: 10
Pharmaceutical Testing Services
Author(s)Pharmaceutical Technology Editors
Galbraith Laboratories, a Bureau Veritas Company, offers a full range of analytical services for pharma, from R&D to final release testing.
Galbraith Laboratories, a Bureau Veritas Company, offers a full range of analytical services for pharma, from R&D to final release testing. Galbraith aims to provide accuracy and speed with its services, which encompass high-quality routine analyses, technically complex projects, custom developed methods, and method validation. Some other services include:
- Chromatography
- Compendial testing
- Elemental analysis
- Forced degradation
- Method development and method validation
- Physical properties
- Spectroscopy
- Stability studies
- Wet chemistry.
As an ISO 17025 accredited and a current good manufacturing practice-compliant laboratory, Galbraith has been providing testing solutions for more than 70 years. Galbraith maintains a long-standing reputation for offering adaptable and solution-driven analytical services, aiming to meet the needs of any client.
Articles in this issue
almost 3 years ago
Leap Yearalmost 3 years ago
Bridging Gaps and Investing in Changealmost 3 years ago
New Therapies Cry Out for New Skillsalmost 3 years ago
Frontrunners in Molecular Gluesalmost 3 years ago
Choosing the Right Excipients for MSC and iPSC Therapiesalmost 3 years ago
Navigating Trends in Secondary Packagingalmost 3 years ago
Bringing Collaboration to the Horizon Once Morealmost 3 years ago
Proving It’s Clean with Analyticsalmost 3 years ago
Finalizing the European Health Data SpaceRelated to this article
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.